1 research outputs found
Supplementary Material for: Contemporary Antiplatelet Treatment in Acute Coronary Syndrome Patients with Impaired Renal Function Undergoing Percutaneous Coronary Intervention
<p><b><i>Objectives:</i></b> To assess the clinical impact of impaired
renal function (IRF), in “real-world” acute coronary syndrome (ACS)
patients, receiving clopidogrel, prasugrel, or ticagrelor. <b><i>Methods:</i></b>
This was a prospective, observational, multicenter, cohort study of ACS
patients undergoing percutaneous coronary interventions (PCI) with IRF
(creatinine clearance <60 mL/min by Cockroft-Gault equation), who
were recruited into the Greek Antiplatelet Registry (GRAPE). Patients
were followed-up until 1 year for major adverse cardiovascular events
(MACE; a composite of death, nonfatal myocardial infarction, urgent
revascularization, and stroke) and BARC (Bleeding Academic Research
Consortium) bleeding. <b><i>Results:</i></b> Out of 2,047 registered
patients, there were 344 (16.8%) with IRF. At the 1-year follow-up, MACE
occurred in 18.6 and 6.2% of those patients with and without IRF,
respectively: adjusted hazard ratio (HR) = 2.13 (95% confidence
interval, CI 1.16-3.91), <i>p</i> = 0.02. IRF patients were also at
higher risk of death and BARC type ≥2 and ≥3 bleeding: adjusted HR =
3.55 (95% CI 1.73-7.27), <i>p</i> = 0.001; HR = 2.75 (95% CI 1.13-6.68), <i>p</i> = 0.03; and HR = 6.02 (95% CI 2.30-15.77), <i>p</i>
< 0.001, respectively. Combined MACE and BARC type ≥2 bleeding
occurred in 34.0 and 14.0% of those with and without IRF, respectively:
adjusted HR = 2.65 (95% CI 1.36-5.16), <i>p</i> = 0.004. At discharge, clopidogrel was more frequently prescribed in IRF patients (61.0 vs. 33.1%, <i>p</i> < 0.001). <b><i>Conclusions:</i></b>
Real-world ACS patients with IRF subjected to PCI demonstrate higher
thrombotic and bleeding risks than patients with normal renal function.</p